Seminars in Hematology
Volume 46, Issue 2 , Pages 133-142 , April 2009

Frontline Treatment in Elderly Patients With Multiple Myeloma

  • Thierry Facon

      Affiliations

    • Service des Maladies du Sang, Centre Hospitalier Universitaire (CHU), Lille, France
    • Corresponding Author InformationAddress correspondence to Thierry Facon, MD, Service des Maladies du Sang, Hôpital Claude Huriez, CHU, rue Michel Polonovski, 59037 Lille, France
    • ,
  • Jesus San Miguel

      Affiliations

    • Hospital Clinico Universitario, Salamanca, Spain
    • ,
  • Maria Victoria Mateos

      Affiliations

    • Hospital Clinico Universitario, Salamanca, Spain
    • ,
  • Cyrille Hulin

      Affiliations

    • Service de Médecine Interne-Hématologie, Centre Hospitalier Universitaire (CHU), Vandoeuvre, France

References 

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma (Intergroupe Francais du Myelome). N Engl J Med. 1996;335:91–97
  2. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600–607
  3. Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant. 2006;37:917–922
  4. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, et al. Treatment for multiple myeloma (Combination chemotherapy with different melphalan dose regimens). JAMA. 1969;208:1680–1685
  5. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657–1664
  6. Facon T, Mary JY, Pegourie B, Attal M, Renaud M, Sadoun A, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006;107:1292–1298
  7. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832–3842
  8. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887–890
  9. Hernandez JM, Garcia-Sanz R, Golvano E, Blade J, Fernandez-Calvo J, Trujillo J, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol. 2004;127:159–164
  10. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571
  11. Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104:1428–1433
  12. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–831
  13. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209–1218
  14. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112:3107–3114
  15. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. The efficacy of melphalan-prednisone plus thalidomide in very elderly patients (< 75 years) with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. In press.
  16. Waage A, Gimsing P, Juliusson G, Turesson I, Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial [abstract 78]. Blood. 2007;110:32a
  17. Gulbrandsen N, Waage A, Gimsing P, Turesson I, Juliusson G, Abildgaard N, et al. A randomised placebo controlled study with melphalan/prednisone vs melphalan/prednisone/thalidomide: quality of life and toxicity [abstract 0209]. Haematologica. 2008;93:84
  18. Wijermans P, Schaafsma M, Van Norden Y, Ammerlaan R, Wittebol S, Sinnige H, et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 study [abstract 649]. Blood. 2008;112:241
  19. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003;1:194–205
  20. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423
  21. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–2622
  22. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377–2380
  23. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136–1144
  24. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006;24:937–944
  25. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165–2172
  26. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008;93:560–565
  27. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917
  28. San Miguel J, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, et al. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma [abstract 650]. Blood. 2008;112:242
  29. Mateos M, Oriol A, Martinez J, Cibeira M, de Paz R, Terol M, et al. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus Velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for Velcade: an alkylating or an immunomodulator agent?. [abstract 651] Blood. 2008;112:243
  30. Palumbo A, Bringhen S, Rossi D, Magarotto V, Di Raimondo F, Ria R, et al. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients [abstract 652]. Blood. 2008;112:243
  31. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–4530
  32. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–3067
  33. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050–4053
  34. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458–3464
  35. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459–4465
  36. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–436
  37. Rajkumar SV, Rosinol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171–2177
  38. Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B. Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2008;Epub ahead of print Oct 27
  39. Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood. 2006;108:2159–2164
  40. Kyriakou C, Thomson K, D'Sa S, Flory A, Hanslip J, Goldstone AH, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol. 2005;129:763–770
  41. Morgan GJ, Davies FE, Owen RG, Rawstron AC, Bell S, Cocks K, et al. Thalidomide combinations improve response rate: results from the MRC IX study [abstract 3593]. Blood. 2007;110:1051a
  42. Morgan JG, Jackson GH, Davies FE, Drayson MT, Owen RG, Gregory WM, et al. Maintenance thalidomide may improve progression free but not overall survival: results from the Myeloma IX maintenance randomisation [abstract 656]. Blood. 2008;112:245
  43. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86:399–403
  44. Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2002;43:1777–1782
  45. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract 74]. Blood. 2007;110:31a
  46. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams MV, et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome [abstract 8504]. J Clin Oncol. 2008;26:455s
  47. Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer. 1988;57:94–99
  48. The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113:1020–1034
  49. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000;11:1427–1436
  50. Schaar CG, Kluin-Nelemans HC, Te Marvelde C, le Cessie S, Breed WP, Fibbe WE, et al. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol. 2005;16:634–639
  51. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99:3163–3168
  52. Shustik C, Belch A, Robinson S, Rubin S, Dolan S, Kovacs M, et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group Study: MY.7 [abstract 6510]. J Clin Oncol. 2004;22:560s
  53. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–3294
  54. Spencer A, Prince M, Roberts A, Prosser I, Bradstock K, Coyle L, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem cell transplantation (ASCT) procedure. J Clin Oncol. In press.
  55. Abdelkefi A, Ladeb S, Torjman L, Ben Othman T, Lakhal A, Ben Romdhane N, et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805–1810

PII: S0037-1963(09)00030-4

doi: 10.1053/j.seminhematol.2009.02.002

Seminars in Hematology
Volume 46, Issue 2 , Pages 133-142 , April 2009

Article Tools